Patents by Inventor Sara Maria Robledo Restrepo

Sara Maria Robledo Restrepo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181626
    Abstract: A use of micro- and nano-MgH2 compound particles in the inhibition of Leishmania infection and in the treatment of Leishmaniasis is provided. The micro- and nano-MgH2 compound particles can be used to prepare a pharmaceutical composition for inhibiting Leishmania or to prepare a pharmaceutical composition for treating a skin or mucosal ulcer or visceral damage caused by Leishmania infection. The present disclosure discovers for the first time that the micro- and nano-MgH2 compound particles can significantly reduce the number of Leishmania in macrophages and inhibit the proliferation of Leishmania, indicating a very prominent insecticidal inhibition effect. The micro- and nano-MgH2 compound particles of the present disclosure can quickly and effectively cure a skin ulcer and/or a mucosal ulcer caused by Leishmania and an impaired function of an internal organ (mainly liver and spleen) caused by Leishmania and have high biosafety and huge clinical application values.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 15, 2023
    Applicant: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Guangyin YUAN, Monica Echeverry RENDON, Liang JIN, Sara Maria Robledo RESTREPO
  • Patent number: 9801895
    Abstract: The cream formulation of the present invention is a topical cream made with antimycotic (amphotericin B) and a mixture of excipients where the water present in the formulation smoothes inflamed tissue. The cream has a particular application for the treatment of cutaneous leishmaniasis and mucosal leishmaniasis in humans and animals. The topical application avoids the risks of toxicity and the gastrointestinal hassles of pills treatments. It has greater acceptability from patient and does not require of valuations before, during or after treatment to check toxicity levels of the liver, kidney and heart.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: October 31, 2017
    Assignees: HUMAX PHARMACEUTICAL S.A., UNIVERSIDAD DE ANTIOQUIA
    Inventors: Ivan Dario Velez-Bernal, Sara Maria Robledo-Restrepo, Martha Beatriz Robledo-Restrepo, Alba Lucia Ceballos-Maya, Newar Andres Giraldo-Alzate, Alvaro Gomez-Zuluaga, Juan Jose Zuluaga-Rivera
  • Patent number: 9168268
    Abstract: SAPONINS AND CHROMANS DERIVATIVES MIXTURE COMPOSITIONS AGAINST LEISHMANIASIS, TRYPANOSOMIASIS AMERICANA, MALARIA, TRYPANOSOMIASIS AFRICANA AND FASCIOLA HEPATICA, is a composition of saponins and chromans derivatives. The saponins are triterpene types and chromans are hydrazones derivatives. This composition is a therapeutic agent against tropical diseases.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: October 27, 2015
    Assignee: Universidad de Antioquia
    Inventors: Luis Fernando Echeverri-Lopez, Winston Quinones-Fletcher, Luis Fernando Torres-Roldan, Rosendo Ricardo Archbold-Joseph, Gustavo Adolfo Escobar-Pelaez, Sara Maria Robledo-Restrepo, Ivan Dario Velez-Bernal, Diana Lorena Munoz-Herrera, Adriana Maria Restrepo-Agudelo, Juan Alejandro Daza-Figueredo, Sergio Andres Pulido-Munoz, Edwin Andres Correa-Garces
  • Patent number: 9145352
    Abstract: The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: September 29, 2015
    Assignees: UNIVERSIDAD DE CALDAS, UNIVERSIDAD DE ANTIOQUIA, THE BOARD OF TRUSTEES OF ILLINOIS STATE UNIVERSITY
    Inventors: Luz Amalia Rios Vasquez, Rogelio Ocampo Cardona, Sandra Milena Duque, Sara Maria Robledo Restrepo, Ivan Dario Velez Bernal, David Leonardo Cedeño Medina, Marjorie Ann Jones
  • Publication number: 20140194640
    Abstract: The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.
    Type: Application
    Filed: May 30, 2012
    Publication date: July 10, 2014
    Inventors: Luz Amalia Rios Vasquez, Rogelio Ocampo Cardona, Sandra Milena Duque, Sara Maria Robledo Restrepo, Ivan Dario Velez Bernal, David Leonardo Cedeño Medina, Marjorie Ann Jones